1
40
6
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2007.07.038" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2007.07.038</a>
Pages
S131–134
Volume
30 Suppl 2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007-12
Subject
The topic of the resource
Adult; Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use; Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use; Bacteria/*drug effects/isolation & purification; Community-Acquired Infections/*drug therapy/microbiology; Humans; Pneumonia/drug therapy/microbiology; Respiratory Tract Infections/*drug therapy/microbiology; Sinusitis/drug therapy/microbiology
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2007.07.038" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2007.07.038</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2007
Adult
Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use
Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use
Bacteria/*drug effects/isolation & purification
Community-Acquired Infections/*drug therapy/microbiology
Department of Internal Medicine
File Thomas M Jr
Humans
International journal of antimicrobial agents
NEOMED College of Medicine
Pneumonia/drug therapy/microbiology
Respiratory Tract Infections/*drug therapy/microbiology
Sinusitis/drug therapy/microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2008.07.019" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2008.07.019</a>
Pages
58–64
Issue
1
Volume
33
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-01
Subject
The topic of the resource
*Anti-Bacterial Agents/pharmacokinetics/therapeutic use; *Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control; *Models; *Pneumonia; Aged; Area Under Curve; Bacterial/drug therapy/microbiology/physiopathology/prevention & control; Biological; Bronchitis; Chronic Obstructive/drug therapy/microbiology/*physiopathology; Chronic/drug therapy/microbiology/physiopathology; Disease Progression; Female; Humans; Lung Diseases/complications/drug therapy/microbiology; Lung/microbiology; Male; Microbial Sensitivity Tests; Middle Aged; Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control; Pneumonia; Pulmonary Disease; Severity of Illness Index; Streptococcus pneumoniae/*drug effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Monte Scott V; Schentag Jerome J; Paladino Joseph A; Klugman Keith P; Lavin Bruce; Yu Victor L; Singer Mendel E; Adelman Martin H
Description
An account of the resource
Patients with chronic obstructive pulmonary disease (COPD) may progress to community-acquired pneumonia (CAP), but there has been no formal study of the factors responsible. We studied the influence of severity of underlying lung disease, pathogen characteristics and the ratio of the area under the concentration-time curve from 0-24h to minimum inhibitory concentration (AUC24/MIC), i.e. the area under the inhibitory curve (AUIC), during the progression from acute exacerbation of chronic bronchitis (AECB) in COPD to CAP. The model parameters were derived from a multinational database of 3885 patients with AECB or CAP (April 1996 to July 2006). Patients with underlying COPD were evaluated in two separate analyses: infection progression between COPD and CAP within Global Initiative for Chronic Obstructive Lung Disease (GOLD)-like grouping (GLG); and distribution of pathogen by GLG, CAP and AECB. Secondary analyses examined the impact of target AUIC attainment on progression to CAP for Streptococcus pneumoniae. The relative impact of GLG and AUIC were modelled in multivariate logistic regression for S. pneumoniae. Progression to CAP linked directly with GLG I/II, III and IV (18.3%, 31.7% and 48.9%, respectively; P \textless 0.001). Progression to CAP was strongly associated with S. pneumoniae (57.3%), whilst other pathogens were predominant in AECB that did not progress to CAP (61.7%) (P = 0.002). AUIC \textgreater or = 100 was associated with AECB (65.1%) and AUIC \textless 100 with CAP (91.7%) (P \textless 0.001). In conclusion, the frequency of progression to CAP increases directly with GLG. For S. pneumoniae, achieving an AUIC \textgreater or =100 can attenuate progression, regardless of GLG. Thus, AUIC \textgreater or = 100 appears to be a viable antibiotic selection strategy to protect patients with S. pneumoniae from developing CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2008.07.019" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2008.07.019</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Anti-Bacterial Agents/pharmacokinetics/therapeutic use
*Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control
*Models
*Pneumonia
2009
Adelman Martin H
Aged
Area Under Curve
Bacterial/drug therapy/microbiology/physiopathology/prevention & control
Biological
Bronchitis
Chronic Obstructive/drug therapy/microbiology/*physiopathology
Chronic/drug therapy/microbiology/physiopathology
Department of Internal Medicine
Disease Progression
Female
File Thomas M Jr
Humans
International journal of antimicrobial agents
Klugman Keith P
Lavin Bruce
Lung Diseases/complications/drug therapy/microbiology
Lung/microbiology
Male
Microbial Sensitivity Tests
Middle Aged
Monte Scott V
NEOMED College of Medicine
Paladino Joseph A
Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control
Pneumonia
Pulmonary Disease
Schentag Jerome J
Severity of Illness Index
Singer Mendel E
Streptococcus pneumoniae/*drug effects
Yu Victor L
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2017.01.043" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2017.01.043</a>
Pages
247–251
Issue
2
Volume
50
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
2017-08
Subject
The topic of the resource
80 and over; Adult; Aged; Anti-Bacterial Agents/adverse effects/*therapeutic use; Atypical pathogen; Bacterial/*drug therapy; Ceftaroline fosamil; Ceftriaxone/adverse effects/*therapeutic use; Cephalosporins/adverse effects/*therapeutic use; Chlamydial Pneumonia; Chlamydophila pneumoniae; Clinical Trials; Combination/adverse effects/methods; Community-Acquired Infections/*drug therapy; Community-acquired pneumonia; Double-Blind Method; Drug Therapy; Female; Humans; Legionella pneumophila; Macrolide; Macrolides/adverse effects/*therapeutic use; Male; Middle Aged; Mycoplasma; Mycoplasma pneumoniae; Phase III as Topic; Pneumonia; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Eckburg Paul B; Talbot George H; Llorens Lily; Friedland H David
Description
An account of the resource
BACKGROUND: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or ceftriaxone treatment in atypical CAP. METHODS: Two phase 3, double-blind, comparative safety and efficacy studies of ceftaroline fosamil vs. ceftriaxone, FOCUS 1 and FOCUS 2, enrolled adults with CAP. Only FOCUS 1 included 24-h adjunctive clarithromycin therapy for all patients on day 1. Day 4 and test-of-cure (TOC) outcomes were compared for adjunctive vs. no adjunctive therapy. RESULTS: Of 1240 enrolled patients, 130 patients with CAP due to atypical pathogens alone were included (FOCUS 1, n = 64; FOCUS 2, n = 66). Among patients infected with Mycoplasma pneumoniae and/or Chlamydophila pneumoniae alone, a higher clinical response rate was observed with clarithromycin plus ceftaroline fosamil or ceftriaxone compared with treatment without additional clarithromycin at day 4 [38/49 (77.6%; FOCUS 1) vs. 24/43 (55.8%; FOCUS 2)], but not at the TOC assessment [42/49 (85.7%; FOCUS 1) vs. 41/43 (95.3%; FOCUS 2)]. In patients infected with Legionella pneumophila alone, a higher clinical response rate with adjunctive clarithromycin therapy was observed at the TOC assessment alone [12/12 (100%; FOCUS 1) vs. 14/19 (73.7%; FOCUS 2)]. The unadjusted odds ratio of a favourable clinical response at day 4 with adjunctive clarithromycin vs. no adjunctive clarithromycin was 2.4 (95% confidence interval 1.1-5.1; P = 0.0299) for all pathogens combined. CONCLUSIONS: These results suggest that empirical antibiotic therapy against atypical pathogens may improve early clinical response rate. This hypothesis is best evaluated in a prospective trial.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2017.01.043" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2017.01.043</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
80 and over
Adult
Aged
Anti-Bacterial Agents/adverse effects/*therapeutic use
Atypical pathogen
Bacterial/*drug therapy
Ceftaroline fosamil
Ceftriaxone/adverse effects/*therapeutic use
Cephalosporins/adverse effects/*therapeutic use
Chlamydial Pneumonia
Chlamydophila pneumoniae
Clinical Trials
Combination/adverse effects/methods
Community-Acquired Infections/*drug therapy
Community-acquired pneumonia
Department of Internal Medicine
Double-Blind Method
Drug Therapy
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Humans
International journal of antimicrobial agents
Legionella pneumophila
Llorens Lily
Macrolide
Macrolides/adverse effects/*therapeutic use
Male
Middle Aged
Mycoplasma
Mycoplasma pneumoniae
NEOMED College of Medicine
Phase III as Topic
Pneumonia
Randomized Controlled Trials as Topic
Talbot George H
Time Factors
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0924-8579(02)00130-9" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0924-8579(02)00130-9</a>
Pages
235–247
Issue
4
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2002
2002-10
Subject
The topic of the resource
*Treatment Outcome; 80 and over; Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use; Amoxicillin/adverse effects/therapeutic use; Bacterial; Bacterial/drug therapy/immunology; Bronchitis/drug therapy/microbiology; Combination/adverse effects/*therapeutic use; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Pneumonia; Respiratory Tract Infections/*drug therapy/metabolism/microbiology; Streptococcal Infections/*drug therapy/metabolism/microbiology; Streptococcus pneumoniae/*drug effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Jacobs Michael R; Poole Michael D; Wynne Brian
Description
An account of the resource
The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant Streptococcus pneumoniae (PRSP) with amoxycillin (+/-clavulanic acid) MICs of
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0924-8579(02)00130-9" target="_blank" rel="noreferrer noopener">10.1016/s0924-8579(02)00130-9</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Treatment Outcome
2002
80 and over
Adolescent
Adult
Aged
Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use
Amoxicillin/adverse effects/therapeutic use
Bacterial
Bacterial/drug therapy/immunology
Bronchitis/drug therapy/microbiology
Combination/adverse effects/*therapeutic use
Department of Internal Medicine
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Drug Therapy
Female
File Thomas M Jr
Follow-Up Studies
Humans
International journal of antimicrobial agents
Jacobs Michael R
Male
Microbial Sensitivity Tests
Middle Aged
Multicenter Studies as Topic
NEOMED College of Medicine
Pneumonia
Poole Michael D
Respiratory Tract Infections/*drug therapy/metabolism/microbiology
Streptococcal Infections/*drug therapy/metabolism/microbiology
Streptococcus pneumoniae/*drug effects
Wynne Brian
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
S57-S57
Volume
26
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Empiric Antibiotic Treatment for Hospital-acquired Pneumonias including Ventilator-associated Pneumonias
Publisher
An entity responsible for making the resource available
International Journal of Antimicrobial Agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005
Subject
The topic of the resource
Infectious Diseases; Microbiology; Pharmacology & Pharmacy
Creator
An entity primarily responsible for making the resource
Tan J S
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2005
Infectious Diseases
International journal of antimicrobial agents
Journal Article
Microbiology
Pharmacology & Pharmacy
Tan J S
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
S59-S59
Volume
26
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
New Treatment Strategies in Acute Bacterial Exacerbation of Chronic Bronchitis
Publisher
An entity responsible for making the resource available
International Journal of Antimicrobial Agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005
Subject
The topic of the resource
Infectious Diseases; Microbiology; Pharmacology & Pharmacy
Creator
An entity primarily responsible for making the resource
Tan J S
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2005
Infectious Diseases
International journal of antimicrobial agents
Journal Article
Microbiology
Pharmacology & Pharmacy
Tan J S